Home | Welcome to Contract Pharma   
Last Updated Tuesday, October 21 2014
Print

Chiltern, Karolinska Development Enter Strategic Partnership



By Kristin Brooks



Published February 12, 2014
Related Searches: Development CRO
Chiltern International Ltd. has entered into a partnership with Karolinska Development in Sweden, a life science investment company, to develop innovations, using world-class science, into products that can be sold or out-licensed with the goal of high returns.
 
"We are extremely pleased to be selected as the partner CRO for Karolinska Development after an extensive CRO selection process in 2012. We were selected based on our compatibility with Karolinska Development's specific development needs in terms of our global company infrastructure and our approach to deliver innovation, quality and flexibility to every project," said Dr. Jim Esinhart, chief executive officer of Chiltern.
 
Aize Smink, Chiltern's chief operating officer, said, "We are honored and proud to be partnering with Karolinska Development, a world-class organization committed to life science innovations and bringing novel therapies to market. A key aspect of our partnering is our early involvement in the development of studies and providing support services and consultation as needed in the product lifecycle. Together, we will work closely with the core team at Karolinska Development to achieve the goals and objectives of their pipeline.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On